Leber Congenital Amaurosis Market - Competitive Dynamics & Global Outlook 2024

Leber Congenital Amaurosis Market: Overview

Leber congenital amaurosis (LCA) is a disorder of eye mainly affects the retina. Retina is the specific tissue at the back of the eye responsible for detection of light and color. People, primarily babies suffering with this disorder have severe visual impairment from the first year of life. The visual impairment because of this disorder likely to be stable for the rest of the life, whereas is some cases it may worsen very slowly over time. LCA is a congenital disease and usually inherited from the parents where both the parents carry a copy of a recessive gene even though they are normal sighted.

The prime symptom of LCA includes lack of visual reactions and unusual eye movements which collectively termed as nystagmus, where it can be observed within the first few months of life, the other secondary symptoms include glaucoma, cataract and cornea problems. Recently companies got experimental successes regarding treatment of LCA using gene therapy, but research and development work on this therapy is still in the research phase.

Leber Congenital Amaurosis Market: Diagnosis and Treatment Demand Drivers

The disease leber congenital amaurosis is very rare and identified at early stage of the life. According to report published by American Association for Pediatric Ophthalmology and Strabismus, approximately 3 cases per 100,000 births have LCA and out of all congenital blindness or severely reduced vision cases in children only 10% are caused by LCA. According to United States Food and Drug Administration, LCA represents more than 5% of all retinal dystrophies.

All these facts represent demand for the various diagnosis and treatment options for leber congenital amaurosis globally in coming future. The technological advancements in diagnosis of LCA and suitable reimbursement circumstances may drive the growth of the market.

Leber Congenital Amaurosis Market: Diagnosis and Treatment Demand Restraints

On the other hand, high cost involved and limited awareness may hinder the growth of the overall market. Currently there is a gene therapy under clinical trial phase for LCA caused genetic mutation in gene RPE65 whereas the clinical study has been completed by QLT Inc. for LCA Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin: Retinol Acyltransferase (LRAT) Mutations and Nantes University Hospital for genetic study of patients suffering from LCA. According to American Society of Gene and Cell Therapy report in June 2014, Spark Therapeutics is planning to commercialize gene therapies for Leber congenital amaurosis in coning future.

Leber Congenital Amaurosis Market: Segmentation

Leber congenital amaurosis market can be segmented according to different categories such as regional geography and market for diagnosis and treatment. Geographically, this market can be segmented in four regions namely North American, Europe, Asia-Pacific and Rest of the World, out of all these segments North America region will highest contribution in terms of value because of more awareness and higher percentage of total income spent on healthcare compared to other economies.

Followed by this, Europe, Asia-Pacific and Rest of the World respectively could be major segments of the market. It is notable that all the companies which are catering in this segment are based out of either in North America or European region, which represents the one sided growth in these particular countries in the near future.

View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13307

Leber Congenital Amaurosis Market: Key Players

Currently very few established players in biotechnology market which are on the way to develop gene therapy products for leber congenital amaurosis. Out of these companies, QLT, Inc., ReGenX Biosciences, LLC, Applied Genetic Technologies Corporation, BBB technologies BV and Spark Therapeutics, LLC have upper hand in this market.

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.

Increasing Healthcare Expenditure Propels Global Healthcare M2M Market

Assisted Living Requirements Propel Adoption of Healthcare M2M Solutions

The increasing number patients in need of assisted living, where first responder connectivity is critical has become the leading factor supporting the growth of healthcare M2M market. The rising trend of wearable devices amongst the health-conscious people has also spurred a demand for healthcare M2M-based solutions as it allows users to track their fitness levels with just a few clicks. The prominence of Internet of Things (IoT) across all verticals is also expected to boost this market in the coming few years. The biggest advantage of M2M-based healthcare services is anticipated to bring down administrative costs and cut down risks pertaining to diagnoses and treatment, which is propelling the market’s growth.

Transparency Market Research states that these factors are likely to provide an opportunity worth US$10.05 bn by the end of 2023 to the global healthcare M2M market. The market was valued at US$1.56 bn in 2014 and is expected to expand at a CAGR of 22.5% between 2015 and 2023.

Patient-Centric Facilities Give Deployment of M2M Solutions in North America a Boost

Regionally, North America is predicted to be the leading segment in the overall market due to a high acceptance of technology and the increasing expenditure on healthcare. TMR says that the North America healthcare M2M market was valued at US$530.7 mn in 2014. However, by the end of 2023, this market is expected to reach US$3.08 bn, expanding at a CAGR of 20.7% from 2015 and 2023. The growing awareness of the benefits M2M-based healthcare solutions can render has led to an increased deployment of these solutions. The patient-centric attitude of facilities has also led a burgeoning demand for M2M solutions in the recent past. This trend will continue to be persistent in the North America market due to a widening pool of geriatrics and growing cases of chronic diseases.

On the other hand, Asia Pacific is projected to be the fastest-growing segment between 2015 and 2023, at a very high double-digit CAGR of 26.9%. This growth will be a result of increasing M2M connections, especially in countries such as Australia, Japan, and China. Furthermore, the growing support from governments to upgrade the healthcare infrastructure and provide affordable healthcare is also anticipated to boost this market in the Asia Pacific region. The medical facilities segment will be the leading segment in Asia Pacific due to a strong presence of service providers, who are outsourcing telehealth services.

Download Complete Healthcare Analytical Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8590

M2M Healthcare Solutions Gain Traction in Sports and Fitness Applications

The patient well-being application segment is gaining is tremendous importance as hospital staffs across the globe operate under high pressure to provide patient care. The ease of operations brought about by M2M-based healthcare solutions in patient care is a welcome change in this high responsibility job, thereby easing the load on staffers. The decreasing dependency of patients on healthcare professionals has add value to the efficiency of the industry. Furthermore, the sports and fitness application is expected to be the leading segment with a robust CAGR of 26.5% during 2015 and 2023.

The key players in the global healthcare M2M market are Sierra Wireless, Inc., Athenahealth, Inc., GE Healthcare, Apple Inc., Cisco Systems Inc., IBM Corporation, Stanley Healthcare, Allscripts Healthcare Solutions Inc., AT&T Inc., and Gemalto NV. Several players designing and developing cloud-based M2M-healthcare solutions to provide a long-term solution that improves the accessibility to the mammoth volumes of healthcare data.

Analgesics Market - Latest Innovations, Drivers, Restraints, Challenges and Forecast 2016 - 2024

Global Analgesics Market: Overview

Analgesics, or painkillers, are used to reduce and treat aches and pains. Internal and external analgesics are used to combat pain resulting from inflammation, cancer treatments, physiological injury, neuropathic conditions, surgeries, wounds, and phantom aches. The most prominent therapeutic classes of analgesics are local anesthesia, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioids. The growing incidence of cancer worldwide and the rise in chronic diseases are mainly responsible for the consistent growth of the global analgesics market.

The research publication offers clients a comprehensive summary of the global analgesics market and elucidates the various factors driving and hampering its growth during the forecast period. The report also evaluates the chief players competing in the global market for analgesics and profiles them on the basis of a number of key attributes, such as company and business overview, recent developments, product portfolio, business strategies, and financial strength.

Global Analgesics Market: Key Trends and Competitive Landscape

The increasing therapeutic benefits offered by analgesics, in addition to effective and fast relief from pain, have significantly driven the demand for analgesics over the years. The development of innovative drugs and rising awareness about these treatment options have also supported the analgesics market. Moreover, the rise in recurring aches and pains owing to an increase in the prevalence of cancer, cardiovascular disease, arthritis, and other chronic and acute diseases has propelled the demand for analgesics. Other key factors positively impacting the global analgesics market include the growing prevalence of pain worldwide, the rise in effective treatment options, a surge in the aging population, and the growing acceptance of analgesics by a wider target audience.

Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Bayer AG, F. Hoffmann-La Roche Ltd., Pfizer Inc., Endo Pharmaceuticals, Reckitt Benckiser plc, Bristol-Myers Squibb, Sanofi, Johnson & Johnson, Novartis AG, and GlaxoSmithKline PLC are some of the major companies actively participating in the global analgesics market. In the quest of increasing their share in the analgesics market, an increasing number of firms have been adopting acquisitions as their main development strategy.

Global Analgesics Market: Region-wise Outlook

The global analgesics market has been categorized into Europe, North America, Asia Pacific, and Rest of the World based on geography. North America is presently the leading market for analgesics and is projected to retain its dominant position through 2024. Recent regulatory changes in the U.S., accompanied by new marketing strategies by analgesics companies, have greatly benefited this regional market. After declining sales owing to frequent recalls, the analgesics market in the U.S., in particular, has been stabilizing on account of the return of prominent brands, the rising occurrence of aches and pains, the rise in the average age of the population, and an alarming rate of obesity. These demographic and lifestyle developments have significantly propelled the North America analgesics market.

The Europe analgesics market is also anticipated to expand in the coming years owing to the rapid commercialization of new drugs and an increasing geriatric population. Although analgesics form one of the largest product areas in over-the-counter drugs, this segment has been negatively affected by the growing trend of improving health instead of merely treating symptoms. An increasing number of consumers in the U.K., for instance, have restricted their consumption of analgesics with this trend in mind, thereby negatively impacting the sales of analgesics.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12113

In contrast, consumers in several Asia Pacific countries seem relatively less concerned over the possible side-effects of analgesics. A higher willingness to self-medicate instead of visiting a trained physician for mild pain and fever is a trend that is common in a number of countries, more prominently in India. Moreover, the immensely stressful lifestyles in most urban parts of the region have resulted in consumers looking for quick and easy solutions to combat pain. This, combined with the surge in purchasing power, has enabled the demand for as well as sales of analgesics to remain steady over the years.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Small Molecule Kinase Inhibitors Market is projected to witness robust growth in the coming years

Small molecule kinase inhibitors are a form of enzyme inhibitors and are mostly used for the treatment of cancer. Protein kinase aids in the development and progression of tumors and small molecule kinase inhibitors help in obstructing unregulated cell cycle. The growing incidenace of cancer cases around the globe is one of the major factors that propel the small molecule kinase inhibitors market. This has driven pharma companies and regulatory bodies to further speed up the process of clinical trials and drug approvals.

The research report analyzing the small molecule kinase inhibitors market studies the industrial landscape and presents a qualitative and quantitative portrait of the expected performance of the market from 2013 to 2019.

The data is derived from primary and secondary research, ensuring absolutely unbiased and authentic evaluation of the small molecule kinase inhibitors market. With the help of Porter’s five forces analysis, the report studies the role of buyers, suppliers, substitutes, new entrants, and competitors in the global market. Growth factors, challenges, and opportunities are identified and discussed at length and added emphasis is laid on government regulations that govern that pharmaceutical industry.

Overview of the small molecule kinase inhibitors market

The small molecule kinase inhibitors market is projected to witness robust growth in the coming years with rising popularity of the next generation of kinase inhibitor drugs, multi-targeted kinase inhibitors, and combination drug therapies. The use of kinase inhibitors for the treatment of various oncology and non-oncology diseases has grown, and while cancer end-use application areas are much stronger, non-cancer therapies are bound to gain interest.

Key kinase inhibitor drugs that have made a significant contribution to the global market include Sorafenib, Gefitinib, Iressa, Temsirolimus, Imatinib, Dasatinib, Rapamycin, Nilotinib, Everolimus, Sunitinib, Erlotinib, and Lapatinib. These commercially-available drugs are designed to target and treat specific diseases. There are numerous small molecule kinase inhibitor drugs in the pipeline, a factor that is anticipated to boost the global market. These pipeline drugs include Pazopanib, Cediranib, CP-690550, Bosutinib, Vandetanib, Alvocidib, Motesanib, and Ridaforolimus.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2110

Despite the availability of a number of kinase inhibitors, the anticipated rise in cancer cases all over the world poses high potential for the growth of the small molecule kinase inhibitors market. However, strict regulatory riders, lengthy approval procedures, and mounting costs of next-generation cancer drugs are matters of concern that hamper the expansion of the small molecule kinase inhibitors market.

Companies mentioned in the research report

Prominent names in the small molecule kinase inhibitors market include Bristol-Myers Squibb, Amgen, KAI Pharmaceuticals, Onyx Pharmaceuticals, Wyeth, OSI Pharmaceuticals, Glaxo SmithKline, Merck & Co, Pfizer, Bayer Schering Pharma, Roche, Sanofi-Aventis, AstraZeneca, Novartis, Genentech, and Celgene Corporation. The research study discusses these companies with respect to company overview, financial standing, product portfolio, recent developments in the small molecule kinase inhibitors market, mergers and acquisitions, business strategies, and SWOT analysis.

Global Biomedical Refrigerators and Freezers Market will amass a prominent share in overall revenues from emerging market

The global market for biomedical refrigerators and freezers has a handful of regional players and only a few international companies, reports Transparency Market Research (TMR) in a recent report. Though regional players command power in their respective countries, giving stiff competition to global ventures with their economical offerings, the market witnessed the dominance of three international companies in 2015 - Thermo-Fisher Scientific, Inc., Panasonic Healthcare Co., Ltd., and Eppendorf AG. Collectively, these international giants accounted for nearly 60% in the global market.

TMR analysts suggest that the global biomedical refrigerators and freezers market will amass a prominent share in overall revenues from emerging markets in the next few years. To appeal to clients and exploit the vast growth opportunities in these regions, leading vendors are being compelled to offer low-priced products and enter into collaborations with promising regional players.

Rise in Research Activities and High Demand for Blood Transfusion and Personalized Medicines to Stimulate Market’s Growth

The demand for biomedical refrigerators and freezers has substantially increased in the past few years, primarily owing to the sustained increase in research activities in the biomedical industry. The rising prevalence of a number of infectious and chronic diseases across the globe, alarming rise in the world’s geriatric population base, and rising healthcare expenditures are pushing the development of healthcare infrastructures across the world. The increased demand for personalized medicines and a vast rise in the numbers of blood transfusions taking place across the globe have further increased the demand for reliable biomedical refrigerators and freezers on a global front.

The market has also benefitted from government initiatives the increased demand for technological upgrades in healthcare infrastructure, especially in emerging economies with flourishing medical tourism industry and a rising population of affluent consumers, in the past few years. However, the market’s development is hindered to a certain extent owing to the high cost of products and rising use of refurbished equipment.

Demand for Environment-friendly Refrigerators and Freezers Gathers Strength

Emission of harmful greenhouse gases is a major concern with conventional refrigerators and freezing equipment. As the concerns and awareness regarding the harmful effects of these emissions to the health of the planet rise globally, the demand for greener equipment is gathering strength. In the next few years, most of the new product designs entering the global biomedical refrigerators and freezers will be greener. The switchover will be expedited by strict government regulations regarding emission control and initiatives from product manufacturers toward innovation.

Plasma Freezers and Blood Banks to Emerge as High-impact Driver

In terms of product types, the segment of plasma freezers presently dominates the global biomedical refrigerators and freezers market. The segment accounted for a share of over 28% in the global market in 2015 and is expected to retain dominance over the forecasting horizon as well, majorly owing to the rising demand for storage of fresh frozen plasma. In terms of application, the market is expected to see the highest revenue flowing in from the blood bank industry in the next few years. The market for biomedical refrigerators and freezers is expected to expand at the fastest rate in Asia Pacific through 2024, although North America will continue to account for a larger share in the market in terms of revenue contribution.

Download Free exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4666

The global market for biomedical refrigerators and freezers held an opportunity of US$2.91 bn in 2015. The market is expected to expand at a 4.21% CAGR over the period between 2016 and 2024, and rise to a valuation of US$4.28 bn by 2024.

This review of the market is based on a recent market research report by Transparency Market Research, titled “Biomedical Refrigerators and Freezers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”

Global Regulatory Affairs Outsourcing Market will exhibit a healthy 11.5% CAGR from 2015 to 2023

In the highly fragmented market for regulatory affairs outsourcing, a very small number of large players have been able to acquire dominant share in the past few years. The top seven companies in the market, including Quintiles Transnational Holdings, Inc., Pharmaceutical Product Development (PPD), LLC, ICON plc, and PAREXEL International Corporation had a combined share of 55% in the global market in 2014. The presence of a large number of small- and medium-size companies in the market grants high bargaining power to buyers/clients. The intense competitive rivalry in the market has increased the number of options to choose from for clients in terms of product differentiation and price.

The scenario calls for regulatory affairs service providers to excel on the metrics of timeliness and quality. As health authorities and compliance agencies now accept electronic submissions, technological advancements will also play a crucial role for regulatory affairs service providers in gaining a competitive edge, states a recent report by TMR.

Cost-efficient Outsource Activities Appeal Companies to Shift from Expensive In-house Regulatory Maintenance

As the medical industry witnesses an increased rate of product innovations from companies wanting to make a mark in the intensely competitive market, investments on R&D activities are skyrocketing. Cost pressures and intense competition in the global market are pushing companies in finding ways of containing costs incurred during the process of undertaking a variety of regulatory operations and practices central to the life sciences industry. Outsourcing, being a cost- and resource-efficient way of cutting costs incurred during the management of the vast data generated during activities such as clinical trials, approvals, and patent approvals, is being increasingly preferred by companies in comparison to in-house data management.

Diverse Regulations Encourage Global Companies to Prefer On-the-ground Expertise

In addition, the presence of strict regulatory framework governing every aspect of development and marketing of medical drugs and devices require that the regulatory documents be in line with defined writing guidelines. This factor has also led to the increased preference for professional service providers focused primarily on handling data related to regulatory affairs, driving the increased need for reliable regulatory affairs outsourcing service providers.

As life sciences companies look forward to spread their business network across the globe, the implications and challenges of managing the diverse and constantly changing local, regional, and national regulations can be overwhelming without on the ground expertise. In this situation, outsourcing regulatory affairs to service providers with a successful global footprint will be the most preferred solution.

Download Complete Healthcare Analytical Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3528

The global regulatory affairs outsourcing market had a valuation of US$1.9 bn in 2014. The market is expected to expand at a substantial 11.5% CAGR from 2015 to 2023 and rise to a valuation of US$5.7 bn by 2023. Rising numbers of low-cost clinical trial centers in emerging economies such as Asia Pacific and Latin America will provide the most lucrative growth opportunities for the market during 2015 to 2023. The market is expected to expand at the highest, 15.8% CAGR, in Asia Pacific during the period. Latin America will follow, exhibiting 11.1% CAGR.

The review is based on a recent market research report published by Transparency Market Research, titled “Regulatory Affairs Outsourcing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023.”

Limitations Associated With Use of Allografts and Autografts to Bring Orthobiologics at Forefront

Orthobiology is a branch of science that develops bone and tissue replacement materials for fasthealing and quick recovery of injured muscles, broken bones, ligaments and tendons. Orthobiologics is considered as a highly lucrative market owing to significant growth opportunities. One of the major driver for the growth of this industry is certain limitations that are associated with autografts and allografts. Although, autografts are considered as gold standard for orthopedic procedures but the usage of autograft involves donor site morbidity and an additional surgery. While, the major concerns associated with allografts is risk of disease transmission along with the decline in theiravailability. Therefore, in order to overcome these drawbacks of the autografts and allografts, bone graft substitutes are being preferred for use in orthopaedic surgery.

According to the American Academy of Orthopedic Surgeons (AAOS), approximately 465,000 spinal surgeries were performed in the U.S in 2011. Of all the spinal fusion surgeries performed, 46% were for lumbar fusion, 42% were for cervical fusion and the remaining 13% were for thoracic or multi-level fusion procedures. This rise in number of spinal fusion surgeries has created the demand for bone graft substitutes and has consequently boosted the overall growth of this industry. In addition, rise in the incidence of arthritis, increase in geriatric population and increase in obesity rate has triggered the growth of this market. Technological advancements, growing demand for minimally invasive procedures and rising patient awareness are the other factors that has considerably augmented the growth of this market. The global orthobiologics market was valued at USD 3,754.6 million in 2012 and is expected to grow at a CAGR of 5.9%from 2013 to 2019 to reach at an estimated value of USD 5,519.9 million in 2019.

At present, viscosupplementation accounts for the largest share of the orthobiologics market. The growth in this market is attributed to growing popularity of knee treatments and its ability to act as an effective pain killer as compared to NSAIDS and others. This market is followed by bone morphogenetic proteins (BMPs) which is characterized by its ability to provide faster recovery, lesser pain and ability to stimulate patients own cells for regeneration. However, the market is expected to show a negative growth rateduring the forecast period due to decline in the sales of “INFUSE” a Medtronic product. Severe side effects associated with INFUSE due to its heavy off label usage led to recall of this product by the U.S FDA. Synthetic bone substitutes and stem cell based products are expected to witness a significant growth during the forecast period. The growth of these segments is witnessed due to reduced cost, quick recovery and eliminated risk of disease transmission.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1747

Geographically, North America and Europe dominates the orthobiologics market. The dominance in these region is witnessed due to rise in incidence of arthritis and higher obesity rates that has surged the demand for minimally invasive procedures such as bone grafting and growth factor treatment. These treatments offer enhanced well-being and durability, with minimal side effects while eliminating the need for repeated hospital visits. However, the Asia-Pacific region is expected to show highest growth rate during the forecast period. The demand for orthobiologics in this region is witnessed due to increase in number of orthopedic disease due to change in lifestyle, change in diet which all lead to increasing obesity rate and consequently leads to arthritis and other bone disorders. Moreover, rise in geriatric population and increase in sports related injuries are other factors likely to drive the growth of orthobiologics in this region.

The major players engaged in the orthobiologics market include Medtronic, Inc., DePuySynthes, Wright Medical Technology, Inc., Stryker Corporation, Orthofix, Inc., NuVasive, Inc., and other significant players.